Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 1,709 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 1,709 shares of the firm’s stock in a transaction on Monday, October 21st. The shares were sold at an average price of $120.76, for a total value of $206,378.84. Following the completion of the transaction, the chief executive officer now owns 194,615 shares in the company, valued at $23,501,707.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Tuesday, October 15th, Steven Leonard Chapman sold 4,523 shares of Natera stock. The shares were sold at an average price of $130.40, for a total value of $589,799.20.
• On Monday, September 16th, Steven Leonard Chapman sold 5,024 shares of Natera stock. The stock was sold at an average price of $128.48, for a total value of $645,483.52.
• On Thursday, August 15th, Steven Leonard Chapman sold 5,583 shares of Natera stock. The stock was sold at an average price of $118.91, for a total value of $663,874.53.
• On Monday, July 29th, Steven Leonard Chapman sold 4,084 shares of Natera stock. The stock was sold at an average price of $102.77, for a total value of $419,712.68.

Natera Stock Performance

NASDAQ NTRA opened at $119.17 on Friday. The company has a market cap of $14.74 billion, a P/E ratio of -48.64 and a beta of 1.53. The company has a debt-to-equity ratio of 0.34, a current ratio of 4.14 and a quick ratio of 4.01. The stock has a 50-day moving average of $123.37 and a two-hundred day moving average of $111.09. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $133.54.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.69) by $0.39. The business had revenue of $413.35 million during the quarter, compared to analysts’ expectations of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The business’s quarterly revenue was up 58.1% compared to the same quarter last year. During the same quarter last year, the business posted ($0.97) EPS. As a group, analysts anticipate that Natera, Inc. will post -1.96 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on NTRA. BTIG Research lifted their price target on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. UBS Group reduced their price target on Natera from $160.00 to $145.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Canaccord Genuity Group raised their price objective on Natera from $130.00 to $145.00 and gave the stock a “buy” rating in a research report on Tuesday, August 27th. StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a research report on Friday. Finally, Leerink Partners raised their price objective on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and a consensus target price of $124.44.

Hedge Funds Weigh In On Natera

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC boosted its stake in shares of Natera by 17.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 10,858 shares of the medical research company’s stock valued at $1,378,000 after buying an additional 1,640 shares during the period. Lake Street Advisors Group LLC boosted its stake in shares of Natera by 7.4% in the 3rd quarter. Lake Street Advisors Group LLC now owns 2,250 shares of the medical research company’s stock valued at $286,000 after buying an additional 156 shares during the period. HWG Holdings LP boosted its stake in shares of Natera by 395.8% in the 3rd quarter. HWG Holdings LP now owns 14,920 shares of the medical research company’s stock valued at $1,894,000 after buying an additional 11,911 shares during the period. Zweig DiMenna Associates LLC lifted its stake in Natera by 213.0% during the third quarter. Zweig DiMenna Associates LLC now owns 242,625 shares of the medical research company’s stock worth $30,801,000 after purchasing an additional 165,100 shares during the last quarter. Finally, International Assets Investment Management LLC lifted its stake in Natera by 9,755.3% during the third quarter. International Assets Investment Management LLC now owns 14,980 shares of the medical research company’s stock worth $1,902,000 after purchasing an additional 14,828 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.